Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
1.34% $1.510
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 44.34 mill |
EPS: | -0.370 |
P/E: | -4.08 |
Earnings Date: | May 14, 2024 |
SharesOutstanding: | 29.36 mill |
Avg Daily Volume: | 0.215 mill |
RATING 2024-04-25 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.08 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.09x |
Company: PE -4.08 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.384 - 1.636 ( +/- 8.34%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-17 | Strobeck Mark | Sell | 6 101 | Common Stock |
2024-03-17 | Timmins Megan C. | Sell | 3 137 | Common Stock |
2024-03-14 | Neri Jesse | Buy | 47 190 | Stock Option (Right to Buy) |
2024-03-14 | Neri Jesse | Buy | 33 330 | Common Stock |
2024-03-14 | Strobeck Mark | Buy | 100 000 | Common Stock |
INSIDER POWER |
---|
98.05 |
Last 94 transactions |
Buy: 5 892 041 | Sell: 1 731 308 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.510 (1.34% ) |
Volume | 0.210 mill |
Avg. Vol. | 0.215 mill |
% of Avg. Vol | 97.71 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.